Abstract: The present invention generally relates to the field of pesticides. More specifically, the present invention relates to novel spinosyn compounds having advantageous properties, processes for their preparation, and their use as pesticides.

Abstract: The present invention generally relates to the field of pesticides. More specifically, the present invention relates to novel spinosyn compounds having advantageous properties, processes for their preparation, and their use as pesticides.

Abstract: The present invention generally relates to the biotechnology engineering, and specifically to genetically modified mesophilic, methylotrophic bacteria, which allow for the production of biochemicals in a pH-independent manner. More specifically, the present invention provides a mesophilic, methylotrophic bacterium which expresses a polypeptide which has glutamate decarboxylase (GAD) activity and is catalytically active at a pH above 5.5. The present invention further provides a mesophilic, methylotrophic bacterium which expresses a) a polypeptide having ?-ketoglutarate decarboxylase (KDC) activity and b) a polypeptide having GABA transaminase (GABA-TA) activity. The present invention also provides methods for the pH-independent production of biochemicals, such as ?-amino butyric acid (GABA) or related compounds, using a bacterium of the invention.

Abstract: The present invention generally relates to the biotechnology engineering, and specifically to a genetically engineered bacterium capable of producing cytokinins with isoprenoid side chains (isoprenoid cytokinins), and the preparation and application thereof.

Abstract: The present invention provides a method of treating a locus against pest infestation using a compound of Formula I as described herein or an agriculturally acceptable salt thereof. The present invention also provides combinations and compositions comprising the compound of Formula I or an agriculturally acceptable salt thereof and uses thereof. The present invention also provides methods of extracting the compound of Formula I from a fungus.

Abstract: The present invention provides a 5-methylfolate producing microorganism which a) has been modified to have a decreased expression and/or activity of a polypeptide having both dihydrofolate synthase activity and folylpolyglutamate synthetase activity compared to an otherwise identical microorganism (reference microorganism); b) has been (further) modified to express a heterologous polypeptide having only dihydrofolate synthase activity; c) has been (further) modified to have an increased expression level of at least one enzyme (such as at least two, at least three, at least four, at least five, at least six, at least seven or at least eight) enzymes involved in the biosynthesis of a 5-methylfolate compared to an otherwise identical microorganism (reference microorganism); and/or d) has been (further) modified to have a decreased expression and/or activity of a polypeptide having 5-methyltetrahydropteroyltriglutamate-homocysteine S-methyltransferase activity compared to an otherwise identical microorganism (ref

Abstract: Provided is a folate producing strain and the preparation and application thereof, in particular, the expression level of the endogenous folC gene in the engineered strain of the present invention is decreased, and the exogenous folC gene is introduced, and the production capacity of the folate, the precursor, or the intermediate thereof in the engineered strain is significantly improved compared to the starting strain.

Abstract: Methods and pharmaceutical compositions for use in treating diseases associated with insufficient activity of the pantothenate kinase enzyme (e.g., CASTOR diseases) are disclosed. The methods and compositions involve an effective amount of an active derivative of 4?-phosphopantetheine.

Abstract: The invention relates to the use of phosphopantetheine compounds alone and in combination with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Preferred medical uses relate to the treatment or prevention of dyslipidemia.

Abstract: Methods and pharmaceutical compositions for use in treating diseases associated with insufficient activity of the pantothenate kinase enzyme (e.g., CASTOR diseases) are disclosed. The methods and compositions involve an effective amount of an active derivative of 4?-phosphopantetheine.

Abstract: This invention provides novel strains of the genus Lactobacillus which can be used to produce pharmaceutical products with probiotic properties for human or veterinary use. The strains of this invention possess metabolic features that are particularly suitable for treatment of disorders related to lactose malabsorption and intolerance, fructose malabsorption and intolerance, and bloating.

Abstract: The invention relates to the use of phosphopantetheine compounds alone and in combination with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Preferred medical uses relate to the treatment or prevention of dyslipidemia.

Abstract: The invention relates to (S)-acyl-4?-phosphopantetheine derivatives, methods of their synthesis, and related medical uses of such compounds. Preferred medical uses relate to the treatment of neurodegenerative diseases, such as PKAN.

Abstract: The invention relates to (S)-acyl-4?-phosphopantetheine derivatives, methods of their synthesis, and related medical uses of such compounds. Preferred medical uses relate to the treatment of neurodegenerative diseases, such as PKAN.

Abstract: The invention provides a fungal cell, such as a yeast cell, capable of growing in co-cultivation with Propionibacterium. Also provided are methods of producing such cells and fermentation processes using the fungal cell of the invention and Propionibacterium in co-cultivation. Such co-cultivation significantly reduces the chemical oxygen demand load of the waste fermentation broth.

Abstract: The invention provides a fungal cell, such as a yeast cell, capable of growing in co-cultivation with Propionibacterium. Also provided are methods of producing such cells and fermentation processes using the fungal cell of the invention and Propionibacterium in co-cultivation. Such co-cultivation significantly reduces the chemical oxygen demand load of the waste fermentation broth.

Abstract: This invention provides novel strains of the genus Lactobacillus which can be used to produce pharmaceutical products with probiotic properties for human or veterinary use. The strains of this invention possess metabolic features that are particularly suitable for treatment of disorders related to lactose malabsorption and intolerance, fructose malabsorption and intolerance, and bloating.

Abstract: The invention relates to (S)-acyl-4?-phosphopantetheine derivatives, methods of their synthesis, and related medical uses of such compounds. Preferred medical uses relate to the treatment of neurodegenerative diseases, such as PKAN.

Abstract: Genetically modified strains of Streptomyces tsukubaensis (S. tsukubaensis) can be used for an improved fermentation process for the preparation of tacrolimus or a salt or derivative thereof by cultivation of these genetically modified strains. Novel genes allowing biosynthesis of allylmalonyl-CoA can be used for polyketide production with allylmalonyl extender unit.

Abstract: Genetically modified strains of Streptomyces tsukubaensis (S. tsukubaensis) can be used for an improved fermentation process for the preparation of tacrolimus or a salt or derivative thereof by cultivation of these genetically modified strains. Novel genes allowing biosynthesis of allylmalonyl-CoA can be used for polyketide production with allylmalonyl extender unit.